February 2019 issue editorial by editor Thierry Heles

January 2019 issue editorial by Thierry Heles, editor, Global University Venturing

The Stanford University-backed fund will halt new investments from July, seemingly as the accelerator reaches financial stability but in the midst of a legal battle.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

November issue editorial by Thierry Heles, editor, Global University Venturing

Introducing the Global University Venturing Powerlist 2018

Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.

October issue editorial by Thierry Heles, editor, Global University Venturing

As MedWhat scores an initial win in its courtroom battle with Stanford, Paige.ai finds itself in the middle of allegations that its licensing deal with Sloan Kettering was improper.

The GUV September issue editorial by Thierry Heles.